annb0t
Top 20
Mesoblast Limited
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed
PDUFA Goal Date August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic âOff-the-Shelfâ Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for...
>>> Read more: FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed
PDUFA Goal Date August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic âOff-the-Shelfâ Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for...
>>> Read more: FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
